Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Liposomal Doxorubicin Market size was valued at USD 1.6 billion in 2024 and is anticipated to surpass USD 3.6 billion by 2037, registering a CAGR of 7% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of liposomal doxorubicin is estimated at USD 1.7 billion.
The demand for the market is remarkably stimulated by the persistent global incidence of cancers. For instance, in May 2024, according to the National Cancer Institute data, there were a projected 9.7 million cancer-related deaths and 20 million new cases worldwide in 2022. This is expected to increase to 15.3 million deaths and 29.9 million new cases by 2040. It thus demands more therapeutically active chemotherapeutic agents with higher therapeutic indices. For instance, in April 2025, Akeso, Inc. is pleased to report that its differentiated PD-1 monoclonal antibody, penpulimab-kcqx, has been approved by the U.S. FDA for use as a first-line treatment for adult recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC).
Moreover, the intricate characteristics of liposomal drug delivery systems through which enhanced drug delivery in tumor microenvironments with less off-target toxicities, such as cardiotoxicity, becomes feasible, are the most impelling force supporting the market growth. For instance, in August 2024, the FDA approved Johnson & Johnson’s RYBREVANT plus LAZCLUZETM as the first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). In addition, increasing trends are towards more clinical usefulness for liposomal doxorubicin, further characterizing the evolving dynamics of liposomal doxorubicin utilization.
Liposomal Doxorubicin Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing R&D investments in oncology: The surging interest in oncology research drives the lucrative investments in the market, which furthers the innovation in treatment modalities and the development of novel drugs. For instance, in April 2025, Boehringer Ingelheim's fully owned subsidiary NBE Therapeutics (NBE) formally opened its new ADC research and development center with a CHF 27 million investment in Basel. This accomplishment reaffirms its dedication to oncology innovation and fortifies its position within Switzerland's biotech sector. Thus, a higher focus on R&D improves patient outcomes and generates new economic value.
- Strategic collaborations and partnerships: The prime drivers of the market growth are strategic alliances and collaborations, which facilitate effortless market entry by leveraging complementary capabilities and resources. For instance, in March 2023, Pfizer Inc. and Seagen Inc. announced that they had reached a final merger agreement, where Pfizer paid USD 43 billion for a total enterprise value to acquire Seagen. This acquisition had been unanimously authorized by the boards of directors of both firms for the discovery of revolutionary cancer medications. Therefore, synergy-based relationships yield dual value creation and long-term expansion.
Challenges
- Scale-up and industrialization: The obstacle in the liposomal doxorubicin market is the rising industrialization issues in the transition of technological innovation to real market impact. The shift from bench-scale feasibility to stable, economically viable production involves judicious process optimisation, stringent quality control standards, and cautious capital expenditure limits the growth. Further, managing intricate interdependencies in stringent regulatory environments, establishing stable supply chains, and cultivating skilled personnel are of overriding importance in delivering sustainable and competitive industrial-scale production.
- Efficacy limitation in certain tumors: In the market, efficacy limitations in certain cancer types are a serious and chronic problem in oncology. These limitations generally occur as a result of multiple mechanisms of intrinsic or acquired resistance, which enable cancer cells to evade the cytotoxic effects of different therapeutic modalities, including chemotherapy, targeted therapies, and even immunotherapies. In addition, the inherent heterogeneity of the tumor cells, as indicated by variations in genetic and epigenetic makeup, causes the heterogeneous response to treatment and resistant clone development to a great extent.
Liposomal Doxorubicin Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7% |
|
Base Year Market Size (2024) |
USD 1.6 billion |
|
Forecast Year Market Size (2037) |
USD 3.6 billion |
|
Regional Scope |
|
Liposomal doxorubicin Segmentation
Application (Leukemia, Breast Cancer, Endometrial Cancer, Gastric Cancer, Liver Cancer, Kidney Cancer)
The liver cancer segment in the liposomal doxorubicin market is anticipated to dominate with 32.2% by the end of 2037, because of the increasing cases of liver cancers. For instance, in March 2023, the National Library of Medicine unveiled that with over 800,000 fatalities each year, liver cancer ranks as the 4th most common cause of death worldwide. Furthermore, the integration of the EPR effect with liposomal products' drug delivery targeting potential enables selective accumulation of doxorubicin in liver tumor tissues with maximum therapeutic effectiveness and potentially lessened systemic toxicities. For instance, in February 2025, Akeso, Inc. reported that the first patient in Australia had been enrolled in the AK138 D1 Phase I clinical trial for the treatment of advanced cancers.
Product (Doxil/Caelyx, Lipodox, Myocet)
Based on the product, the Lipodox segment is anticipated to garner a major share in the liposomal doxorubicin market during the stipulated timeframe, stemming primarily from the clinical efficacy of novel drugs. This growth is further supplemented by brand identification, name, and established channels of distribution. For instance, in August 2024, Lupin Limited announced the introduction of Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials in the US. This accumulated clinical evidence and market infrastructure most likely contribute to its widespread application by healthcare professionals.
Our in-depth analysis of the global market includes the following segments:
|
Application |
|
|
Product |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportLiposomal Doxorubicin Industry - Regional Synopsis
North America Market Statistics
The liposomal doxorubicin market in North America is expected to maintain its dominance during the forecast timeline, i.e., from 2025 to 2037, with a notable share of 40.3%, owing to its higher effectiveness in treating Kaposi Sarcoma. Moreover, this growth is driven by the improvements in medication formulations, which draw funding for novel drugs from prominent key regional players. In addition, the shifting focus on enhancing cancer treatments is likely to spur the growth of the market in the near future.
The U.S. market is exponentially growing, fueled by the persistent research and development initiatives taken by the reputable organizations and companies in improving treatment efficacy. For instance, in April 2025, according to the findings presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, which took place from April 25 to 30, a new gene expression atlas created using single-cell RNA sequencing data illustrates how normal hematopoietic cells differentiate. This investigation was used to catalog multiple ways that aberrant differentiation can result in acute myeloid leukemia (AML).
The Canada market is experiencing remarkable growth during the projected timeframe, attributable to the preventive steps taken by organizations to disseminate awareness amongst their people. For instance, in December 2024, initiatives to enhance breast cancer outcomes and promote innovation in screening and treatment was announced by the Canadian charity Breast Cancer Canada. These efforts include focusing on early detection and prompt access to care, equipping patients with tools and education, and accelerating innovation through grant programs. The organization's emphasis on precision oncology and its dependence on donor finance serve as additional testaments to its dedication.
Asia Pacific Market Analysis
The Asia Pacific liposomal doxorubicin market is growing at a remarkable pace during the anticipated timeline, due to the demand for innovative diagnostic equipment. This growth is further attributable to the proliferation of generic versions of life-saving drugs, greater patient understanding of viable therapies. Moreover, contemporary healthcare facilities, and growing healthcare expenses boost the market demand.
The India market is experiencing a phenomenal growth trend, driven chiefly by surging cancer cases in the country, coupled with expanding healthcare infrastructure to combat the concerning cause. For instance, in February 2025, it was unveiled that in India, in 2023, there were an expected 14 lakh cancer cases, according to the Indian Council of Medical Research (ICMR). In addition, the Union Budget 2025–2026 highlights the local government’s commitment to improving cancer care through opening 200 day care cancer centers in district hospitals. Moreover, it intends to render 36 cancer, rare disease, and chronic disease medications completely exempt from Basic Customs Duty (BCD), and provide a 5% customs duty discount on six life-saving medications.
The China liposomal doxorubicin market is demonstrating remarkable growth, mainly due to the strong presence of key players who are striving to maintain their strong market base by offering reliable therapeutic measures. For instance, in November 2024, the 2024 Top 100 Chinese Pharmaceutical Innovative Enterprises award was given to Alphamab Oncology during the 16th China Healthcare Summit of Entrepreneurs, Scientists, and Investors (2024 CHSESI). The four indicators such as, the number of authorized patents, the total number of patent citations, the number of clinical trials, and the number of innovative drugs approved and commercialized, are used as the foundation for this ranking.
Companies Dominating the Liposomal Doxorubicin Landscape
- Pfizer Inc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Sun Pharmaceutical Industries Ltd
- Cipla Inc
- Cadila Pharmaceuticals
- SRS Life Sciences
- GSK plc
- Sanofi
- Sigma-Aldrich Co.
- Merck & Co., Inc
The competitive landscape of the pharmaceutical business makes the liposomal doxorubicin market extremely dynamic and capital-intensive. Businesses also collaborate and combine with other companies, strengthening their foundations and expanding their capacity for production and distribution. For instance, in October 2024, an agreement was finalized between Sanofi and Orano Med to pool their knowledge in the battle against uncommon malignancies and hasten the creation of next-generation radioligand medications.
Here's the list of some key players:
In the News
- In December 2024, Affinity Biopharma revealed that it had successfully raised more than 55 USD million in its Series B2 fundraising round. The goal was to address the significant and pressing clinical needs in the field of tumors.
- In March 2024, Fusion Pharmaceuticals Inc., has reached a final agreement to be acquired by AstraZeneca. The acquisition marks a significant step toward its goal of revolutionizing cancer treatment and patient outcomes by substituting more specialized treatments.
Author Credits: Radhika Pawar
- Report ID: 7623
- Published Date: May 08, 2025
- Report Format: PDF, PPT
